

## Press Release

BioLeap, Inc. announces **the Addition of Dr. Gene Cordes to its Board of Directors**  
**Ewing, NJ. May 3, 2010**

[BioLeap, Inc.](#), a drug design company that leverages its proprietary technology platform to conceive structurally-diverse, target-specific chemical entities, today announced that Dr. Gene Cordes has joined its Board of Directors.

“Gene Cordes brings us decades of industry experience, a solid understanding of good board governance, and an open and inquisitive mind willing to explore novel solutions to pressing industry problems,” said Bill Frezza, General Partner at Adams Capital Management and Chairman of BioLeap’s Board.

“I am excited by the opportunity to work with Gene” says David Pompliano, CEO of BioLeap. “His experience and guidance will prove invaluable to our mission of changing the drug discovery paradigm.”

Gene has 20 years of management experience in the pharma industry: Vice-President for Biochemistry and Molecular Biology in the Merck Research Laboratories; President of R&D and corporate Vice-President at Sterling Winthrop Pharmaceuticals; Chairman of the Board at Vitae Pharmaceuticals. Gene served nine years on the Board of Directors at Millennium Pharmaceuticals and currently is a Director at Vertex Pharmaceuticals. Gene has published more than 120 papers in referred scientific journals and has authored a number of books.

Gene also has 24 years of experience in the academic world at Indiana University and the University of Michigan. He has served on several advisory committees to academic institutions and governmental agencies. Dr. Cordes was educated at Caltech (BS in Chemistry, 1958) and Brandeis University (PhD in Biochemistry, 1962). He received an Honorary Doctor of Science degree from the University of Nebraska in 2009.

### **About BioLeap, Inc.:**

BioLeap is a drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap’s design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap’s technology provides a viable alternative to high-throughput screening and traditional shape-based “docking” approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.

### **Company Contact:**

Gerry Evans, EVP  
BioLeap, Inc.  
215-693-6340  
ghe@bioleap.com